The effect of Huoxinfang on inflammatory factors and arteries in patients with coronary heart disease and angina pectoris

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13004040

Enrollment

Unknown

Registered

2013-12-19

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease and angina pectoris

Interventions

control:Basic treatment

Experimental:Basic treatment + Huoxinfang

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 75 years; (2) Patients should be diagnosed with coronary heart disease and chronic stable angina; (3) Patients should be diagnosed with thoracic obstruction; (4) Patients should be diagnosed with qi-stagnancy and blood stasis,stagnation of endogenous retention of phlegm; (5) Written informed consent was obtained from all patients.

Exclusion criteria

Exclusion criteria: (1) Patients complicated by cardiovascular and cerebrovascular diseases,hepatic disease hematopoietic system desease, and others; (2) Patients complicated by diabetes complications, High blood pressure complications, and others; (3) Patients complicated by infections, electrolyte disturbance, and others; (4) Patients complicated by mental disease; (5) Pregnant and breastfeeding women; (6) Patients who is unfavorable for clinical trials.

Design outcomes

Primary

Measure	Time frame
Echocardiography;Inflammatory cytokine analysesis;Arterial function;Traditional Chinese medicine symptom score;quality of life evaluation;Security Index;	—

Countries

China

Contacts

Public ContactYan Xu

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

13918172520@163.com+86 21-20256175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026